2.59

1.37% 0.035

After Hours: 2.58 -0.010 -0.39%

Compugen Ltd (CGEN)

Overview News Price History Option Chain Discussions Forecast

Compugen Ltd stock is traded at $2.59, with a volume of 199.70K. It is up +1.37% in the last 24 hours and up +8.82% over the past month. Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Previous Close:

$2.555

Open:

$2.54

24h Volume:

199.70K

Relative Volume:

0.58

Market Cap:

$245.35M

Revenue:

$72.66M

Net Income/Loss:

$34.86M

P/E Ratio:

7.0765

EPS:

0.366

Net Cash Flow:

$-62.91M

1W Performance:

-0.38%

1M Performance:

+8.82%

6M Performance:

+21.03%

1Y Performance:

+83.69%

1-Day Range:

$2.54

$2.61

1-Week Range:

$2.52

$2.66

52-Week Range:

$1.295

$3.235

Compugen Ltd Stock (CGEN) Company Profile

Name

Compugen Ltd

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

Address

Employee

Twitter

@CompugenLtd

Next Earnings Date

2026-08-03

Latest SEC Filings

CGEN's Discussions on Twitter

Compare CGEN vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEN Compugen Ltd	2.59	251.03M	72.66M	34.86M	-62.91M	0.366
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Compugen Ltd Stock (CGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-07-26	Initiated	Lake Street	Buy
Jan-07-26	Initiated	H.C. Wainwright	Buy
Jan-13-25	Initiated	Oppenheimer	Outperform
Aug-05-22	Downgrade	Jefferies	Buy → Hold
May-26-20	Resumed	JMP Securities	Mkt Outperform
May-13-20	Initiated	Stifel	Buy
May-07-20	Initiated	SVB Leerink	Outperform
Apr-22-20	Initiated	ROTH Capital	Buy
Mar-24-20	Initiated	SunTrust	Buy
Jan-16-20	Initiated	Cantor Fitzgerald	Overweight
Mar-29-18	Initiated	Oppenheimer	Outperform
Feb-01-16	Resumed	Oppenheimer	Outperform
Oct-15-15	Initiated	FBR Capital	Outperform
Apr-23-15	Resumed	Jefferies	Buy
Apr-21-15	Initiated	Oppenheimer	Outperform
Feb-07-14	Initiated	MLV & Co	Buy
Dec-28-09	Reiterated	Cantor Fitzgerald	Buy
Jul-29-09	Initiated	Cantor Fitzgerald	Buy

View All

Compugen Ltd Stock (CGEN) Latest News

Aug 21, 2026

Are Medical Stocks Lagging Compugen (CGEN) This Year? - Yahoo Finance

Aug 21, 2026

Aug 18, 2026

Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayCost Structure Review - dars.gov.et

Aug 18, 2026

Compugen (CGEN) Dips 2.49% to $2.35, Pressure Mounts Toward Support at $2.23Price Target - vinanet.vn

Aug 18, 2026

Aug 16, 2026

Analysts Have Just Cut Their Compugen Ltd. (NASDAQ:CGEN) Revenue Estimates By 14% - simplywall.st

Aug 16, 2026

Aug 15, 2026

CGEN Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprises PositivelyMargin Expansion Trends - vinanet.vn

Aug 15, 2026

Aug 14, 2026